Stine Høj
Biographic Data
| ID | 6078385 |
|---|---|
| NAME | Stine Høj |
| GIVEN NAMES | Stine |
| FAMILY NAME | Høj |
| SIGNATURE | HØJ S |
| AFFILIATIONS | Brendan Jacka, Stine Hoj, and Julie Bruneau are with Research Center of the Centre Hospitalier de l’Université de Montréal, Montréal, Quebec. Canada. Sarah Larney and Louisa Degenhardt are with National Drug and Alcohol Research Centre, UNSW Sydney, NSW, Australia. Naveed Janjua and Mel Krajden are with British Columbia Centres for Disease Control, Vancouver, British Columbia, Canada. Jason Grebely is with The Kirby Institute, UNSW Sydney. |
| VERIFIED | No |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 6 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2009 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
A scoping review and concept analysis to inform Canada’s safe(r) opioid supply research agenda
Safe(r) supply encompasses prescribed opioid alternatives interventions (safer supply) and non-medicalized (safe supply) approaches with shared antecedents but distinct attributes and consequences. This study highlights the need to better define and standardize the parameters of safer supply approaches, including population, dosing, and intended objectives, to enable a more precise assessment of their potential benefits and risks. This nuanced un…
A rapid review of the impacts of “Big Events ” on risks, harms, and service delivery among people who use drugs: Implications for responding to Covid-19
BACKGROUND: "Big Events" are major disruptions to physical, political, and economic environments that can influence vulnerability to drug-related harms. We reviewed the impacts of Big Events with relevance to the COVID-19 pandemic on drug-related risk and harms and access to drug treatment and harm reduction services. METHODS: We conducted a rapid review of quantitative, qualitative, and mixed methods literature relating to the following Big Even…
Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs
Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada
Objectives. To determine the number of people who inject drugs (PWID) in Canada and the annual coverage of opioid agonist treatment (OAT) and needle-and-syringe provision for PWID. Methods. We estimated the number of PWID in 11 of 13 Canadian provinces and territories in 2011 by using indirect multiplier methods based on provincial and territorial methadone recipient totals and proportion of surveyed PWID receiving methadone. We modeled annual in…
Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs
Communicating the Sustainability Message to the Public: Lessons from Marketing
No prominent works on this page.
Communicating the Sustainability Message to the Public: Lessons from Marketing
Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs
Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs
Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada
Objectives. To determine the number of people who inject drugs (PWID) in Canada and the annual coverage of opioid agonist treatment (OAT) and needle-and-syringe provision for PWID. Methods. We estimated the number of PWID in 11 of 13 Canadian provinces and territories in 2011 by using indirect multiplier methods based on provincial and territorial methadone recipient totals and proportion of surveyed PWID receiving methadone. We modeled annual in…
A rapid review of the impacts of “Big Events ” on risks, harms, and service delivery among people who use drugs: Implications for responding to Covid-19
BACKGROUND: "Big Events" are major disruptions to physical, political, and economic environments that can influence vulnerability to drug-related harms. We reviewed the impacts of Big Events with relevance to the COVID-19 pandemic on drug-related risk and harms and access to drug treatment and harm reduction services. METHODS: We conducted a rapid review of quantitative, qualitative, and mixed methods literature relating to the following Big Even…
A scoping review and concept analysis to inform Canada’s safe(r) opioid supply research agenda
Safe(r) supply encompasses prescribed opioid alternatives interventions (safer supply) and non-medicalized (safe supply) approaches with shared antecedents but distinct attributes and consequences. This study highlights the need to better define and standardize the parameters of safer supply approaches, including population, dosing, and intended objectives, to enable a more precise assessment of their potential benefits and risks. This nuanced un…
Environmental health (4 works) · HIV, Drug Use, Sexual Risk (4 works) · Medicine (4 works) · Business (2 works) · Hepatitis C (2 works) · Hepatitis C virus (2 works) · Hepatitis C virus research (2 works) · HIV/AIDS Research and Interventions (2 works) · Opioid Use Disorder Treatment (2 works) · Psychological intervention (2 works)